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S100A8/A9 increases the mobilization of
pro-inflammatory Ly6Chigh monocytes to
the synovium during experimental
osteoarthritis
Niels A. J. Cremers1, Martijn H. J. van den Bosch1, Stephanie van Dalen1, Irene Di Ceglie1, Giuliana Ascone1,
Fons van de Loo1, Marije Koenders1, Peter van der Kraan1, Annet Sloetjes1, Thomas Vogl2, Johannes Roth2,
Edwin J. W. Geven1, Arjen B. Blom1 and Peter L. E. M. van Lent1*
Abstract
Background: Monocytes are dominant cells present within the inflamed synovium during osteoarthritis (OA). In
mice, two functionally distinct monocyte subsets are described: pro-inflammatory Ly6Chigh and patrolling Ly6Clow
monocytes. Alarmins S100A8/A9 locally released by the synovium during inflammatory OA for prolonged periods
may be dominant proteins involved in stimulating recruitment of Ly6Chigh monocytes from the circulation to the
joint. Our objective was to investigate the role of S100A8/A9 in the mobilization of Ly6Chigh and Ly6Clow monocytic
populations to the inflamed joint in collagenase-induced OA (CiOA).
Method: S100A8 was injected intra-articularly to investigate monocyte influx. CiOA was induced by injection of
collagenase into knee joints of wild-type C57BL/6 (WT), and S100a9-/- mice. Mice were sacrificed together with age-
matched saline-injected control mice (n = 6/group), and expression of monocyte markers, pro-inflammatory cytokines,
and chemokines was determined in the synovium using ELISA and RT-qPCR. Cells were isolated from the bone marrow
(BM), spleen, blood, and synovium and monocytes were identified using FACS.
Results: S100A8/A9 was highly expressed during CiOA. Intra-articular injection of S100A8 leads to elevated expression
of monocyte markers and the monocyte-attracting chemokines CCL2 and CX3CL1 in the synovium. At day 7 (d7) after
CiOA induction in WT mice, numbers of Ly6Chigh, but not Ly6Clow monocytes, were strongly increased (7.6-fold) in the
synovium compared to saline-injected controls. This coincided with strong upregulation of CCL2, which preferentially
attracts Ly6Chigh monocytes. In contrast, S100a9-/- mice showed a significant increase in Ly6Clow monocytes (twofold)
within the synovium at CiOA d7, whereas the number of Ly6Chigh monocytes remained unaffected. In agreement with
this finding, the Ly6Clow mobilization marker CX3CL1 was significantly higher within the synovium of S100a9-/- mice. Next,
we studied the effect of S100A8/A9 on release of Ly6Chigh monocytes from the BM into the circulation. A 14% decrease
in myeloid cells was found in WT BM at CiOA d7. No decrease in myeloid cells in S100a9-/- BM was found, suggesting
that S100A8/A9 promotes the release of myeloid populations from the BM.
Conclusion: Induction of OA locally leads to strongly elevated S100A8/A9 expression and an elevated influx of Ly6Chigh
monocytes from the BM to the synovium.
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Background
Osteoarthritis (OA) is a chronic degenerative disease of
the joints and currently its high prevalence increases
even further due to aging and an increasingly obese
population [1–3]. Current treatment options focus on
targeting the symptoms and are limited to analgesics
and anti-inflammatory drugs, with many patients
eventually having to undergo joint replacement sur-
gery [4–6]. Novel therapies that focus on preventing
joint damage are warranted. A better insight into the eti-
ology and disease progression is therefore needed [3, 4].
The etiology of OA is multi-factorial, and it is consid-
ered to be a disease of the whole joint in which the
synovium also plays an important role [7–9]. Synovial
activation is clearly present in more than 50% of patients
with OA and contributes to the pathophysiology and
clinical symptoms [6–10]. Systemic and local synovial
inflammation is increasingly recognized to be involved
in joint pathologic change [6, 11, 12]. Although most
types of leucocytes have been described to be present
within the inflamed OA synovium, monocytes and mac-
rophages are thought to be the predominant cell types
driving the pathologic change [13–15]. OA is character-
ized by joint damage, which leads to the release of pro-
teins or alarmins such as S100A8/A9 promoting
activation of monocytes/macrophages within the syno-
vium followed by an inherent release of inflammatory
cytokines, such as IL-1β, TNF-α and additional release
of S100 alarmins [7, 9, 10, 16]. The most prominent pro-
teins from the S100 family that are released during OA
are S100A8 (myeloid-related proteins: MRP8) and
S100A9 (MRP14), which belong to the group of
damage-associated molecular patterns proteins (DAMPs)
or alarmins, and play a crucial role in innate immunity
[17–19]. S100A8 and S100A9 form heterodimers under
low calcium conditions within the cell and assemble into
(S100A8/A9)2 hetero-tetramers in the presence of cal-
cium [20]. When myeloid cells are stressed S100A8/A9
is secreted and binds to the toll-like receptor (TLR)4 re-
ceptor promoting pro-inflammatory effects [19, 21]. We
previously described that S100A8/A9 proteins are
expressed for prolonged periods in collagenase-induced
OA (CiOA), a model driven by synovial inflammation,
and that they are important stimulators of tissue path-
ology [22–24]. In addition, patients with OA are charac-
terized by high levels of S100A8/A9 in blood and
synovium, and baseline serum levels of patients with
symptomatic OA predict development of joint destruc-
tion 2 years thereafter [22, 23]. Moreover, S100A8/A9
promotes the migration of monocytes, which when acti-
vated, are also important producers of S100A8/A9
thereby forming a positive feedback loop [25, 26].
Monocytes are recruited from the bone marrow (BM) to-
wards the site of inflammation via a combined action of
adhesion molecules, e.g. LFA-1 and VCAM, and chemo-
kines, such as (C-C motif) ligand 2 (CCL2) that is known
to bind the C-C chemokine receptor type 2 (CCR) [27–30].
In mice, two functionally distinct monocyte subpopulations
are described. The pro-inflammatory Ly6Chigh monocytes,
which express high levels of CCR2, are involved in remov-
ing debris, and the Ly6Clow monocytes, which express high
levels of CX3CR1, are suggested to be involved in repair
processes as they release anabolic factors like vascular
endothelial growth factor (VEGF) and transforming growth
factor (TGF)-β [31, 32]. Ly6Chigh monocytes reside in the
BM and upon release from the BM into the circulation can
either stay in their state or transform into Ly6Clow mono-
cytes [32, 33]. Once in the blood, both Ly6Chigh as Ly6Clow
monocytes can be mobilized to the peripheral tissue in re-
sponse to chemokines [34]. Ly6Chigh monocytes are mainly
attracted by CCL2 and Ly6Clow monocytes by CX3CL1,
which can bind to CCR2 and CX3CR1, respectively [35].
When the monocytes arrive at the injured site, they can dif-
ferentiate into M1-like pro-inflammatory or M2-like anti-
inflammatory macrophages, dependently on the environ-
mental cues [33]. The aim of our study is to investigate
whether local production of S100A8/A9 in the inflamed
joint and their subsequent release into the circulation is in-
volved in recruitment of the different monocyte cell popu-
lations to the joint in inflammatory CiOA.
Methods
Animals
The Committee for Animal Experiments of the Dutch Cen-
tral Commission on Animal Experiments approved all pro-
cedures involving animals (CCD# 2015-0014). One
hundred fifty-eight female mice (strain: 106 C57BL/6 and
52 S100a9-/-), 8–12 weeks of age, and weighing 21 ± 1.5 g
(minimum 19 g, maximum 26 g) were provided with stand-
ard diet and water ad libitum and maintained on a 12-h
light/dark cycle under specific pathogen-free housing con-
ditions at the Central Animal Facility Nijmegen. More de-
tails on the housing conditions have been previously
described [36]. S100a9-/- mice were originally generated at
the University of Münster as previously described [37]. An
overview of the animals used for the different experiments
and analyzed time-points can be found in Table 1. No ani-
mals died during the experiments and no animals were ex-
cluded during the experiments or data analysis. All mice
were randomly divided over the experiments and different
conditions. All outcomes were measured by an observer
who was blinded to the allocation of the animals to the ex-
perimental groups, when possible. The mice were anesthe-
tized with 5% isoflurane in O2/N2O and killed by
exsanguination, followed by cervical dislocation. At the end
of the experiment, at day 7, 21, or 42 after induction of
CiOA, different tissues (synovium, blood, and contralateral
femur) were collected and used for histologic evaluation,
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collection of serum for protein analysis, measurement of
messenger RNA (mRNA) expression, and determination of
different cell populations.
Collagenase induced OA model and tissue isolation
CiOA was unilaterally induced in wild-type (WT)
C57BL/6 mice by injection of one unit of collagenase
type VII from Clostridium histolyticum (Sigma Chemical
Co., St. Louis, MO, USA) in a volume of 6 μL twice on
alternate days in the right knee joint, as previously de-
scribed [38]. An equal volume of saline was injected into
the right knee of age-matched mice and served as the
treated control. Mice were killed at different time points
(day 7, 21, or 42) after CiOA induction, and the different
readouts as described in Table 1 were determined. In
short, mRNA expression (reverse transcription quantita-
tive PCR (RT-qPCR)) and protein levels (Luminex/
ELISA) of mobilization markers and pro-inflammatory
cytokines, including S100A8 and S100A9, were mea-
sured in the synovium and BM cells isolated from the
contralateral femur. Synovial biopsies were taken using a
3-mm-diameter biopsy punch. The absolute number of
cells in the contralateral BM per femur was determined
by crushing the complete femur with a mortar and pes-
tle, intensive lavation with PBS, and counting of the
cells. Monocyte subpopulations of BM cells present in
the contralateral femur, and CiOA-affected synovial tis-
sue were analyzed by FACS. Tissue sections were stained
with hematoxylin and eosin (HE) and histologically
scored for synovial activation (number of cell layers of
synovial intima lining), and immunohistochemically
stained for S100A8, S100A9 and Ly6C.
Intra-articular injection of S100A8 protein
Mice were injected intra-articularly with a volume of
6 μL PBS containing 5 μg of S100A8 recombinant pro-
tein in the right knee and 5 μg bovine serum albumin
(BSA) protein as a control in the left knee, after which
the mice were killed and synovium was isolated for
histologic evaluation and for RT-qPCR analysis as de-
scribed in Table 1.
RNA isolation and RT-qPCR
Total RNA from BM cells was isolated using TRIzol re-
agent according to the manufacturer’s protocol (Invitro-
gen). Cells of the synovial tissue were lyzed and
homogenized using ceramic MagNa Lyser Green Beads
(Roche) and the MagNa Lyser (Roche) three times for
20 s at 6000 rpm with 1 min interspersed cooling. RNA
of the synovium was further extracted with the RNeasy
Fibrous Tissue mini kit (Qiagen, catalog (cat) # 74704,
Venlo, The Netherlands). DNase treatment (Qiagen:
RNase-Free DNase Set) was performed between the first
washing steps with RW1 buffer. RNA concentration was
determined using the nanodrop 2000 spectrophotometer
(Thermo Scientific). For the reverse transcriptase treat-
ment, 1 μg sample RNA was linearized in a volume of
11 μL water for 15 min at 65 °C and then together with
total reverse transcriptase mix (containing 100 μM DTT,
10 mM dNTP each, 0.2 μg oligodT primer, 20 units
RNA inhibitor (RNAsin: Promega cat # N251A), and
200 units reverse transcriptase (Invitrogen 28025-013))
in a total volume of 20 μL incubated for 5 min at 25 °C,
60 min at 39 °C and 5 min at 94 °C. Hereafter the com-
plementary DNA (cDNA) was diluted × 20 and used for
Table 1 Overview of animals used in experiments
Experiment Readout Time point Number of animals per group
and strains
CiOA/control Monocyte populations and RNA expression
synovium and BM
Day 7 6 CiOA/6 control C57BL/6
6 CiOA/6 control S100a9-/-
CiOA/control BM count Day 7, 21, and 42 6 CiOA/7 control C57BL/6 (day 7)
6 CiOA/7 control C57BL/6 (day 21)
7 CiOA/7 control C57BL/6 (day 42)
CiOA/control Monocyte populations and BM count Day 7 5 CiOA/5 control C57BL/6
5 CiOA/5 control S100a9-/-
CiOA Immunohistologic evaluation
(and serum for protein analysis)
Day 7, 21, and 42 10 per time-point C57BL/6 (day 7)
10 per time-point S100a9-/- (day 7)
10 per time-point C57BL/6 (day 21)
10 per time-point S100a9-/- (day 21)
10 per time-point C57BL/6 (day 42)
10 per time-point S100a9-/- (day 42)
i.a. injection with S100A8/BSA Immunohistologic evaluation Day 1 8 C57BL/6
i.a. injection with S100A8/BSA RNA expression Day 1 6 C57BL/6
CiOA collagenase-induced osteoarthritis, i.a., intra-articular, BM bone marrow
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RT-qPCR, using the StepOnePlus Real-Time PCR Sys-
tem (Applied Biosystems). The reaction was performed
in a volume of 10 μL containing 3 μL cDNA, 0.6 μM
primers, 5 μL iQ SYBR Green Supermix (Bio-Rad La-
boratories). After incubation of 3 min, amplification was
carried out for 40 cycles of 15 s at 95 °C and 30 s at 60 °
C. The melting temperature of the products was defined
to indicate amplification specificity. All values were nor-
malized to the reference gene Gapdh, which is often
used in CiOA experiments and showed stable expression
during this model, and was presented as –Δ cycle
threshold (–ΔCt) [39]. We decided to present the nega-
tive ΔCt (Ct of the reference gene minus the Ct of the
gene of interest) to improve the ease of interpretation
(higher values in the graphs representing higher expres-
sion). Fold change can be calculated as the difference in
−ΔCt (giving ΔΔCt) between saline vs CiOA or WT vs
S100a9-/- groups, and then 2ΔΔCt. Primers are summa-
rized in Table 2. All primers were custom-designed
using Primer-BLAST (https://www.ncbi.nlm.nih.gov/
tools/primer-blast/) at standard settings with a product
size of 70–150 bp, spanning an exon-exon junction, max
poly-X at 4, max GC in primer 3’ end at 3, and primer
GC content between 20 and 80%, and subsequently vali-
dated in serial dilutions of mice cDNA to test the ampli-
fication efficiency of the RT-qPCR. For an efficiency of
100%, the slope is − 3.32; all our primers passed the min-
imal efficiency requirements of 90–110%, corresponding
with a slope between − 3.58 and − 3.1. All primers were
checked for specificity by performing a melt curve, con-
firming a single product after the PCR assay and no for-
mation of aspecific by-products.
Histologic evaluation of total knee joints
Dissected total knee joints were fixed in 4% formalin,
decalcified in 5% formic acid, and subsequently embed-
ded in paraffin. Coronal knee joint sections of 7 μm
thickness were made and mounted on superfrost glass
slides (SuperFrost® Plus, Menzel-Glaser, Germany).
Deparaffinized sections were stained with HE. Synovial
activation was evaluated by two blinded observers scor-
ing the thickening of the synovial lining layer (number
of cell layers of the intima) and the cellular influx as de-
scribed previously [40].
Immunohistochemical staining of S100A8, S100A9, and
Ly6C
Knee joints sections were stained for S100A8, S100A9,
and Ly6C as described previously [22]. In short, antigen
retrieval was performed by incubating for 15 min in cit-
rate buffer at 60 °C. Thereafter, sections were incubated
for 1 h with the primary antibodies directed against
Table 2 Primer sequences of mouse inflammatory and mobilization markers
Sense Antisense
Reference gene
Gapdh 5′-ggcaaattcaacggcaca-3′ 5′-gttagtggggtctcgctcctg-3′
Inflammation marker
S100A8 5′-tgtcctcagtttgtgcagaatataaat-3′ 5′-tttatcaccatcgcaaggaactc-3′
S100A9 5′-ggcaaaggctgtgggaagt-3′ 5′-ccattgagtaagccattcccttta-3′
Mobilization markers
CCL2 5′-ttggctcagccagatgca-3′ 5′-cctactcattgggatcatcttgct-3′
CX3CL1 5′-gtgccattgtcctggagac-3′ 5′-catttctccttcgggtcag-3′
KC 5′-tggctgggattcacctcaa-3′ 5′-gagtgtggctatgacttcggttt-3′
MIP-1α 5′-caagtcttctcagcgccatatg-3′ 5′-tcttccggctgtaggagaagc-3′
Cell markers
CX3CR1 5′-gagtatgacgattctgctgagg-3′ 5′-cagaccgaacgtgaagacgag-3′
CCR2 5′-ctatctgctcaacttggccatct-3′ 5′-tgagcccagaatggtaatgtga-3′
Ly6C 5′-gcagtgctacgagtgctatgg-3′ 5′-actgacgggtctttagtttcctt-3′
F4/80 5′-aatcctgtgaagatgtgg-3′ 5′-gagtgttgatgcaaatgaag-3′
Adhesion molecules
LFA1 5′-gaatgtatgaagggcaaagtc-3′ 5′-gcagcaaactggtaggaag-3′
VCAM 5′-ccaagtctctccaaaagatatacagctt-3′ 5′-atgacggtgtctccctct-3′
L-selectin 5′-actgctctgttgtgacttcc-3′ 5′-tgtatggcgactaaatctgtg-3′
PECAM1 5′-tccctgggaggtcgtccat-3′ 5′-gaacaaggcagcggggttta-3′
VE-cadherin 5′-tcctcttgcatcctcactatcaca-3′ 5′-gtaagtgaccaactgctcgtgaat-3′
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mouse S100A8 (host, rabbit), mouse S100A9 (host,
rabbit) (both were made at our own facilities [41], and
used at a concentration of 1 μg/mL), or mouse Ly6C
(host, rat) (Abcam cat # 15627, at a concentration at
2 μg/mL). Rabbit (for S100A8 and S100A9) or rat (for
Ly6C) IgG antibody was used as a control. After wash-
ing, S100A8 and S100A9 sections were incubated with
horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (Dako, Glostrup, Denmark) for 30 min. For
the Ly6C staining, after incubation with the primary
antibody, and washing, sections were incubated with
secondary rabbit anti rat IgG biotin-labeled antibody for
30 min, followed by washing and a 30-min incubation
with VECTASTAIN elite ABC HRP kit (Peroxidase,
Rabbit IgG) (Vector laboratories, Burlingame, CA, USA,
cat # PK6101). Sections were peroxidase-stained using
diaminobenxidine and counterstained using Mayer’s
hemotoxylin (Biochemica, Amsterdam, the Netherlands).
Determination of monocyte subpopulations using flow
cytometry
Cells isolated from the BM and synovial tissues were ana-
lyzed for monocyte subpopulations by seven-color staining
and flow cytometry using the Gallios flow cytometer (Beck-
man Coulter, Indianapolis, IN, USA). The antibodies and
fluorophores that were used are summarized in Table 3.
First, single cells were selected using the side scatter and
pulse width. Next, viable cells were gated using the side scat-
ter and negative for the SYTOX blue viability staining. Mye-
loid cells, were gated negative for the dump channel (CD90/
B220/CD49b/NK1.1) to deplete T cells, B cells, and natural
killer (NK) cells, and positively selected for CD11b. Cells
were next plotted for Ly6G and Ly6C to distinguish neutro-
phils and monocytes, respectively. Monocytes were selected
and finally plotted for F4/80 and Ly6C. Herein, Ly6Chigh and
Ly6Clow monocytes and macrophages could be selected
dependent on the tissue. Monocyte subsets were identified
as (B220/CD90/CD49b/NK1.1/Ly6G)lowCD11bhigh(F4/80/
MHCII/CD11c)low and further distinguished by their Ly6C
expression, using Kaluza flow cytometry analysis software
(Beckman Coulter).
Statistics
Data were analyzed using GraphPad Prism 5.01 software
(San Diego, CA, USA). Outliers were tested using
Grubbs’ test, but no outliers were found. Data were ana-
lyzed using the two-sided t test to compare two variables
or one-way analysis of variance when comparing mul-
tiple variables. Bonferroni’s multiple comparison post
hoc test was applied as correction for multiple compari-
sons when investigating multiple dependent research
questions. Results were considered significantly different
at p < 0.05 (with significance level denoted as *p < 0.05,
**p < 0.01, and ***p < 0.001).
Results
Increased numbers of monocytes in the synovium after
induction of CiOA coincides with high levels of S100A8/
A9
We first investigated whether monocytes are attracted to
the inflamed joint in experimental inflammatory OA. At
day 7 after induction of CiOA, the number of cell layers
in the intima-lining layer was increased and mainly con-
sisted of leucocytes with monocyte morphology. Most of
the cells within the synovial lining strongly expressed
Ly6C, a protein characteristic of monocytes, as shown
by immuno-localization (Fig. 1a vs control b).
Next we studied whether S100A8/A9 expression was re-
lated to this increase in monocyte numbers within the in-
flamed joint. mRNA levels of S100A8 and S100A9 were
strongly enhanced (35-fold and 60-fold, respectively) at
CiOA day 7, when compared to saline-injected controls
(Fig. 1e). Immuno-localization shows that S100A8/A9 pro-
tein was strongly expressed by monocytes within the in-
flamed synovial lining (Fig. 1c vs control d). At later time
points after CiOA, S100A8/A9 levels were still high whereas
Table 3 Antibodies used to detect monocyte subsets using flow cytometry
Marker Fluorophore Manufacturer (catalog number)
CD11b FITC BD Biosciences (553310)
Ly6C APC-Cy7 BD Biosciences (560596)
Ly6G APC Biolegend (127614)
CD90.2 PE BD Biosciences (553006)
B220/antiCD45 PE BD Biosciences (553090)
CD49b PE BD Biosciences (553858)
NK1.1 PE BD Biosciences (553165)
F4/80 PE-Cy7 Biolegend (123114)
MHCII PE-Cy7 Biolegend (116420)
CD11c PE-Cy7 BD Biosciences (558079)
SYTOX Blue Dead Cell Stain SYTOX blue Thermo Fisher Scientific (S34857)
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Fig. 1 S100A8/A9 mRNA and protein expression is strongly increased in the synovium at day 7 of collagenase-induced osteoarthritis (CiOA), leading to
elevated Ly6Chigh monocytes locally into the joint. a Monocytes are strongly infiltrated during early CiOA as shown by highly expressed Ly6C protein
staining and based on cell morphology in the synovial lining layer of the knee joints at CiOA day 7. b IgG control staining for the Ly6C antibody of the
same joint shows no aspecific staining. c S100A9 protein is expressed in synovial monocytes at CiOA day 7 as shown by immuno-localization. d IgG
control staining for the S100A9 antibody of the same joint shows no aspecific staining. e S100A8 and S100A9 mRNA expression is strongly induced in
the synovium at CiOA day 7 when compared to saline-injected controls. f, g Monocyte marker Ly6C, and the more monocyte-subset-specific markers,
CCR2 (Ly6Chigh) and CX3CR1 (Ly6Clow) are strongly induced (f), together with the monocyte attracting chemokines CCL2 (Ly6Chigh) and CX3CL1
(Ly6Clow) (g) in synovium at CiOA day 7, when compared to saline-injected controls. h Monocyte gating strategy for flow cytometric analysis: single
viable cells were plotted for B220/CD90/CD49b/NK1.1/Ly6G and CD11b, in which myeloid cells were selected, and next the monocyte subsets could
be identified based on their F4/80/MHCII/CD11c and Ly6C expression. i The relative number of Ly6Chigh monocytes were increased, whereas Ly6Clow
monocyte subpopulations remained unaffected locally in the joint at CiOA day 7 compared to saline-injected controls, as observed using flow cytometry.
Data represent mean ± SD of five individual mice. *Significantly different from saline-injected control (**p< 0.01, ***p< 0.001). Ct cycle threshold
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in contrast IL-1β, TNF-α and IL-6 rapidly decreased [22],
suggesting that synovial inflammation in CiOA is dominated
by S100A8/A9 production.
To analyze the presence of pro-inflammatory Ly6Chigh
monocytes and reparative Ly6Clow monocyte subsets, we
next investigated mRNA expression within the inflamed
synovium of chemokine receptors associated with spe-
cific monocyte subsets (Fig. 1f ). Ly6Chigh monocytes are
characterized by expression of mainly CCR2 and to a
lesser extent CX3CR1, whereas Ly6Clow monocytes pre-
dominantly express CX3CR1. mRNA expression levels
of Ly6C, CCR2, and CX3CR1 were all strongly increased
within the inflamed synovium of early-phase CiOA (day
7) (21-fold, 61-fold, and 103-fold, respectively) (Fig. 1f ).
Next we analyzed monocyte-subset-attracting chemo-
kines (Fig. 1g). CCL2 (MCP-1) is dominant for Ly6Chigh
monocytes, whereas CX3CL1 particularly attracts
Ly6Clow monocytes. mRNA expression levels of CCL2
were strongly increased (165-fold), whereas CX3CL1
was only increased 13-fold (Fig. 1g). The strongly in-
creased expression of both CCR2 and its ligand CCL2
within the inflamed synovium suggests an elevated pres-
ence of Ly6Chigh monocytes.
Specifically, Ly6Chigh monocytes are increased in the
synovium after induction of CiOA
To analyze more accurately which monocyte subsets are
indeed preferentially increased within the inflamed syno-
vium during the first phase of CiOA, we treated synovial
tissue obtained from mice with CiOA and saline-
injected control mice with collagenase and analyzed the
cell composition by flow cytometry. Single viable cells
were selected, after which myeloid cells were identified
as CD11bhigh and B220/CD90/CD49b/NK1.1/Ly6Glow to
exclude B cells, T cells, NK -cells, and neutrophils. Next,
monocytes subsets can be further divided based on their
Ly6C expression (Fig. 1h). In synovium at CiOA day 7,
the number of Ly6Chigh monocytes was significantly in-
creased (764% increase) in contrast to Ly6Clow mono-
cytes, which were not different in synovium obtained
from saline-injected control mice (Fig. 1i).
Intra-articular injection of S100A8 protein induces
expression of monocyte markers in the synovium
Since influx of Ly6Chigh monocytes coincides with high
S100A8/A9 levels, we next investigated whether
S100A8/A9 is able to regulate monocyte influx. We
injected S100A8 (5 μg), which is described to be the
most dominant form of the S100A8/A9 complex in mice
[21], or BSA as control, into the knee joint of naive mice
and determined the expression of several markers in-
volved in monocyte attraction in the synovium after
24 h, using RT-qPCR (Fig. 2a-f ). To get an impression
whether monocytes are present, we first measured
mRNA levels of Ly6C and F4/80. Significant upregula-
tion of both Ly6C and F4/80 (2.1-fold and 3.7-fold, re-
spectively) was observed (Fig. 2a and b).
mRNA levels of the Ly6Chigh monocyte-attracting che-
mokine CCL2 and its receptor CCR2 were significantly
elevated (7.8-fold and 4.1-fold, respectively) after
S100A8 injection (Fig. 2c and d). In contrast, mRNA
levels of the Ly6Clow-attracting chemokine CX3CL1 and
its receptor CX3CR1 were lower and were not statisti-
cally significant (1.8-fold and 2.1-fold, respectively)
(Fig. 2e and f). To verify that monocytes are indeed re-
cruited to the joint in response to S100A8 injection, we
stained sections of the joints with HE 24 h after S100A8
injection. Figure 2g clearly shows the strong presence of
inflammatory cells exhibiting typical monocyte morph-
ology, which resided particularly in the synovial lining
layer. This influx of inflammatory cells was absent in
BSA-injected controls (Fig. 2h).
Locally induced CiOA leads to a significant S100A8/A9-
driven decrease of Ly6Chigh monocytes in the BM, but not
in the blood and spleen
As injection of S100A8 into the mouse knee joint leads
to attraction of Ly6Chigh monocytes particularly, we next
investigated the role of S100A8/A9 on monocyte sub-
populations during early CiOA in more detail. To this
end, we used S100a9-/- mice, which functionally are
double knockout for S100A8 and S100A9, since S100A8
is missing at protein level as well [37].
Locally induced inflammation in the joint may have an
impact on migration of monocytes from the BM into the
blood, and subsequently to the inflamed joint. Local in-
duction of CiOA resulted in elevated levels of S100A8/
A9 (up to 882 ng/mL and on average 502 ng/mL) in the
blood at day 7 (Additional file 1: Figure S1) and induced
systemic effects within the BM of WT mice. Measuring
the total number of myeloid cells within a complete
femur at several time points after induction of OA in
WT mice demonstrated a reduction in myeloid cell
number of 14% (p = 0.0210), 14% (p = 0.0205), and 15%
(p = 0.1335) at day 7, 21, and 42 after CiOA induction,
respectively (Fig. 3a), corresponding to release of
Ly6Chigh monocytes at day 7 (p = 0.0616), day 21 (p =
0.0036), and day 42 (p = 0.3982) (Fig. 3b), which only
was significant at day 21, as determined by flow cytome-
try (Fig. 3c). In contrast, no changes in absolute myeloid
cell numbers or Ly6Chigh monocytes were observed in
the femurs of S100a9-/- mice at CiOA day 7 when com-
pared to their saline-injected controls. This suggests that
S100A8/A9 stimulates the efflux of monocytes from the
BM into the blood. However the increase of monocytes
into the blood at this time-point had no effect on the ra-
tio of Ly6Chigh and Ly6Clow subsets in both the blood
(Fig. 3d) and in the spleen (Fig. 3e). No difference was
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found at day 7 CiOA when compared to saline injected
controls, and also not between WT and S100a9-/- mice
(see Fig. 3f and g for the monocyte gating strategy of the
blood and spleen, respectively, using flow cytometry).
Increased numbers of Ly6Clow, but not Ly6Chigh
monocytes in the synovium of day 7 CiOA in S100a9-/-
mice
As we observed differences in BM efflux between WT and
S100a9-/- mice, we additionally studied whether there also
was a difference in cell influx into the synovium between
these two strains. At day 7 after induction of CiOA in
S100a9-/-, a lower number of inflammatory cells with
monocyte morphology was observed in histological sec-
tions within the synovium when compared to WT mice
(Fig. 4a vs WT b). We next studied mRNA expression of
monocyte subset chemokine receptors and their ligands
within the CiOA synovium of S100a9-/- mice (Fig. 4c). Ex-
pression levels of Ly6Chigh monocyte chemokine CCL2
and its receptor CCR2 were similar in S100a9-/- and WT
mice at CiOA day 7. In contrast, Ly6Clow chemokine
CX3CL1 was significantly increased (1.9-fold) in S100a9-/-
mice at CiOA day 7, whereas the mRNA expression of
Ly6Clow monocyte chemokine receptor CX3CR1 was
similar in WTand S100A9 mice at CiOA day 7.
Finally, synovium obtained from S100a9-/- mice at CiOA
day 7 was shortly treated with collagenase and the num-
bers of Ly6Chigh and Ly6Clow monocytes in the synovium
were analyzed by flow cytometry (Fig. 4d). At day 7 CiOA
in WT mice we found a significant rise in Ly6Chigh mono-
cytes, whereas Ly6Clow were not altered when compared
to saline-injected WT mice. Interestingly, in S100a9-/-
mice, levels of Ly6Chigh monocytes were not altered when
compared to saline-injected controls, whereas there was a
significant increase in Ly6Clow monocytes (205%).
Taken together, locally induced S100A8/A9 production
in early OA causes influx of Ly6Chigh monocytes particu-
larly, which are responsible for early production of cyto-
kines and tissue damage. Moreover, inhibition of
S100A8/A9 might give preference to influx of Ly6Clow
monocytes, thereby regulating repair.
Discussion
Recent studies have shown that synovitis significantly
contributes to the development of pathologic change in
the joint during inflammatory osteoarthritis [6]. Previ-
ously, we demonstrated that the alarmin S100A8/A9 plays
an important role in synovitis and joint pathologic change
in CiOA [22]. In the present study, we further explored
the involvement of S100A8/A9 in the recruitment of
monocyte subpopulations towards the synovium in CiOA.
Our findings suggest that prolonged S100A8/A9 produc-
tion during induction of inflammatory OA locally leads to
strongly elevated mobilization of predominantly Ly6Chigh
monocytes into the joint in OA and from the BM.
The monocyte is the major inflammatory cell type
within the synovium throughout the course of inflamma-
tory OA [13–15]. In the mouse, two types of monocytes
have been described. Ly6Chigh monocytes, expressing high
levels of CCR2 and guided by chemokine CCL2 are in-
volved in removing tissue debris and produce mainly pro-
inflammatory cytokines like IL-1β and S100A8/A9. In
contrast, Ly6Clow monocytes, expressing high levels of
CX3CR1 and attracted by CX3CL1, release anabolic fac-
tors like VEGF and TGF-β, involved in repairing joint
tissue [31, 32].
The relative number and the interplay between
Ly6Chigh and Ly6Clow monocytes within the synovium
determine the severity of inflammation and regulate fur-
ther development of pathologic change in the tissues.
Previous studies in our laboratory showed that selective
removal of resident lining macrophages prior to induc-
tion of CiOA largely inhibited monocyte cell influx and
development of joint destruction [40, 42].
In OA, resident synovial macrophages that cover the
surface of the synovium are the first cells cleaning the
extracellular matrix (ECM) fragments released by dam-
aged joint tissue [43]. These fragments are recognized by
TLRs and scavenger receptors, leading to activation of
synovial macrophages thereby releasing high levels of
CCL2. This elevates influx of Ly6Chigh monocytes favor-
ing further removal of tissue debris.
On the other hand, a shift towards higher numbers of
Ly6Chigh monocytes within the inflamed synovium may
foster pathologic change in the joint by elevated release
of pro-inflammatory cytokines. However, only low levels
of cytokines like TNF-α, IL-1β, and IL-6 were observed
during the first phase of CiOA and probably are only
marginally involved in driving pathologic change in the
joint. Induction of CiOA in mice lacking IL-1α/β had no
(See figure on previous page.)
Fig. 2 Intra articular injection of S100A8 leads to local induction of monocytes in the synovium. a-f mRNA expression of monocyte marker Ly6C (a),
macrophage marker F4/80 (B), Ly6Chigh chemokine CCL2 (c), and Ly6Chigh chemokine receptor CCR2 (d) are increased in the synovium of mice 24 h after
intra articular injection with S100A8, compared to BSA-injected controls, whereas Ly6Clow chemokine CX3CL1 (e), and Ly6Clow chemokine receptor CX3CR1
(f) are not affected after S100A8 administration, as analyzed using RT-qPCR. Data represent mean ± SD of six individual mice. *Significantly different from
treated control (*p< 0.05). g, h HE staining on histological sections of the joint 24 h after intra-articular (i.a.) injection with S100A8 demonstrated strong
presence of inflammatory cells with monocyte-like morphology in the synovial lining layer of the knee joints (g), whereas BSA injection as control resulted
in less pronounced presence of inflammatory cells (h). Ct cycle threshold
Cremers et al. Arthritis Research & Therapy  (2017) 19:217 Page 9 of 15
D E
A B
BMC
Blood
Spleen
F
G
Fig. 3 (See legend on next page.)
Cremers et al. Arthritis Research & Therapy  (2017) 19:217 Page 10 of 15
effect on either synovitis or on joint pathology [44]. The
outcome was similar using IL-6-/- and TNF-α-/- mice
(manuscript in preparation). In contrast, alarmin
S100A8/A9 was very strongly upregulated within the
synovium and measured in significant amounts for pro-
longed periods up till day 42 after CiOA induction. The
heterodimer is released by monocytes and activated
macrophages and stimulates nearby synovial cells via
TLR4 to release chemokines that attract monocyte pop-
ulations [45, 46].
In the present study we found that levels of CCL2,
attracting Ly6Chigh monocytes, are much higher in day 7
(See figure on previous page.)
Fig. 3 The number of Ly6Chigh monocytes decreases during collagenase-induced osteoarthritis (CiOA) in the bone marrow (BM) of wild-type (WT) but not
S100a9-/- mice, but not in the blood and spleen of WT or S100a9-/- mice. a The relative number of myeloid cells in the complete contralateral femur of WT
mice was decreased early during CiOA compared to saline-injected controls, whereas no effects were found in S100a9-/- mice at CiOA day 7. b The relative
number of Ly6Chigh monocytes in the complete contralateral BM of WT mice was also decreased early during CiOA compared to saline-injected control
animals, whereas no effect was observed in S100A9-/- mice. c Gating strategy of monocyte subsets in the BM, using flow cytometry. d, e The relative
number of Ly6Chigh and Ly6Clow monocyte subpopulations was not affected in the peripheral blood (d), and spleen (e) at CiOA day 7 in WT or S100a9-/-
mice when compared to saline-injected control animals. f, g Gating strategy of monocyte subsets in the peripheral blood (f) and spleen (g), measured
using flow cytometry. Data represent mean ± SD of 5–7 individual mice per group (except for WT mice on day 7 where n = 11–12 animals). *Significantly
different from saline-injected control (*p< 0.05, **p< 0.01, ***p< 0.001)
A
B
C D
Fig. 4 S100a9-/- mice have locally more Ly6Clow monocytes in early collagenase-induced osteoarthritis (CiOA), compared to wild-type (WT) mice
at CiOA day 7. a, b Less influx of inflammatory cells in S100a9-/- (a) mice compared to WT mice (b) at CiOA day 7, as shown by HE staining. c
mRNA expression of the Ly6Clow monocyte-subset-attracting chemokine CX3CL1 is increased in the synovium of S100a9-/- mice compared to WT
mice at CiOA day 7, while Ly6Chigh monocyte-subset-attracting chemokine CCL2 and both monocyte subset cell markers CCR2 (Ly6Chigh) and
CX3CR1 (Ly6Clow) were not different between the two strains. d Relative number of Ly6Chigh monocytes are increased locally in the joint of WT
mice, whereas Ly6Clow monocytes are increased in S100a9-/- mice, compared to saline-injected controls, as analyzed by flow cytometry. Data
represent mean ± SD of five individual mice per group. *Significantly different from saline-injected control (*p < 0.05, ***p < 0.001)
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CiOA compared to saline-injected controls in WT mice,
resulting in increased presence of Ly6Chigh monocytes in
the synovium. In addition, CCL2 expression was strongly
enhanced in the synovium after i.a. injection of S100A8,
pointing towards an important role for S100A8/A9 in
this process. Whereas in synovium at day 7 CiOA, ex-
pression of CCR2/CCL2, characteristic of Ly6Chigh
monocytes, was comparable in both WT and S100a9-/-
mice, the Ly6Clow-attracting chemokine CX3CL1 and
Ly6Clow monocyte population was raised in the syno-
vium of S100a9-/- mice. Since Ly6Chigh monocytes were
not elevated in S100a9-/- synovium, but the Ly6Clow
monocytes were, S100A8/S100A9 may favor the pres-
ence of Ly6Chigh monocytes within the inflamed syno-
vium, not only by chemotactic attraction but also by
suppressing their differentiation into the Ly6Clow popu-
lation thereby maintaining the monocyte population into
a more pro-inflammatory state.
Recently it was shown that monocytes have a memory,
which is triggered by TLR4 ligands like lipopolysacchar-
ide (LPS) [47]. This memory is initiated by epigenetic
programming and may drive monocytes into a cell type
that sustains its pro-inflammatory characteristics [48].
S100A8/A9 is an important TLR4 ligand released in high
levels for prolonged periods in the joint in OA and may
be a major mediator driving this epigenetic program-
ming. Ly6Chigh monocytes are high producers of
S100A8/A9, which may form a positive feedback loop.
Finally Ly6Chigh and Ly6Clow monocytes are possibly
able to differentiate into M1-like and M2-like macro-
phages, respectively [49, 50]. The local environment
within the synovium strongly influences the signature of
the monocytes and their differentiation into their mature
forms [50, 51].
BM and spleen form important reservoirs for Ly6Chigh
monocytes, which become available under inflammatory
conditions. Local induction of CiOA causes high levels
of S100A8/A9 within the synovium for prolonged pe-
riods; up to 5 μg/mL have been measured in synovial
washouts of CiOA synovium [52]. These proteins leak
from the joint into the blood and elevated levels of
S100A8/A9 levels were measured throughout the course
of OA until the endpoint at day 42. Other pro-
inflammatory cytokines like IL-1β, TNF-α, or IL-6 were
not detected within the blood.
Interestingly local induction of CiOA in the knee joints
of WT mice induced a significant efflux of Ly6Chigh
monocytes from the BM into the blood when compared
to saline-injected WT mice, which was absent at CiOA
day 7 in S100a9-/- mice. This indicates that low-grade local
joint inflammation in OA is able to initiate release of
Ly6Chigh monocytes from the BM. This is in agreement
with an earlier study showing that locally induced low-
grade inflammation in the heart in myocardial infarction
[32, 53] induced efflux from the BM resulting in elevated
local influx of Ly6Chigh monocytes within the lesions.
Which mechanisms that are initiated within the inflamed
joint drive monocyte efflux from the BM is momentarily
under investigation. In contrast to conventional pro-
inflammatory cytokines, which were undetectable in the
blood, S100A8/A9 levels were very high during the course
of CiOA. S100A8/A9 in the blood is not only transported
as a free protein but also inside extracellular vesicles
(EVs). EVs, released by activated immune cells like mono-
cytes/neutrophils, have been shown to contain S100A8/
A9 [54, 55]. They are released at local inflammatory sites
and additionally transported to distant areas where they
can affect other cells by either fusion with their membrane
or when recognized by receptors [54, 55]. In addition,
mechanisms like sympathetic nerve signaling may explain
part of the systemic effects observed in the BM. Earlier
studies suggested that myocardial infarction liberates
monocytes from the BM due to sympathetic nerve signal-
ing thereby boosting atherosclerosis in which pathologic
change is highly regulated by the influx of monocyte sub-
populations [53].
Myeloid precursors in the BM differentiate into Ly6Chigh
monocytes driven by growth factors like PU.1, and M-CSF.
Local inflammation promotes the release of Ly6Chigh
monocytes from the BM into the circulation where they ei-
ther remain in that state or are transformed into Ly6Clow
monocytes [32]. Interestingly, S100a9-/- mice did not have
elevated efflux of monocytes at CiOA day 7. S100A8/A9 is
also abundantly expressed within the BM. Systemic inflam-
matory triggers and/or sympathetic nerve signaling may
promote local release of S100A8/A9 heterodimer within
the BM stimulating migration of Ly6Chigh monocytes to
the blood. This is supported by our findings that expression
levels of LFA-1 (Integrin-β2), VCAM, L-selectin, PECAM1,
and VE-cadherin were significantly decreased in the BM of
S100a9-/- mice (Additional file 1: Figure S2). It is described
that all these adhesion molecules contribute to leucocyte
adhesion and migration in the BM [34, 56]. S100A8/A9
alarmins are strong activators of the beta-2 integrin on
myeloid cells and have been shown to be important in
transendothelial migration of phagocytes [26, 57–59].
Moreover, previous studies have already shown that
S100A8/A9 drives primary BM expansion of myeloid-
derived suppressor cells (MDSC) driven by the S100A9/
CD33 pathway thereby altering hematopoiesis [60].
Apart from the BM the spleen also forms an important
reservoir for storage of Ly6Chigh monocytes [61] and
may contribute to sustaining synovitis in OA. Although
it is described that acute inflammation promotes mono-
cyte release from the spleen [62], we did not find any ef-
fect on the ratio of monocyte populations in the spleen
of mice at CiOA day 7. This is in agreement with an
earlier study in which it was found that in a more severe
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model of arthritis, splenectomized mice did not differ
in ankle swelling or clinical score compared to non-
splenectomized mice [63], suggesting that monocytes
released from the spleen do not contribute to synovial
inflammation in arthritis.
Although BM efflux of monocytes was significantly
raised at CiOA day 7, no effect on the ratio of monocyte
subsets was observed within the blood. Although the data
as presented in this manuscript strongly suggest a role for
S100A8/A9 in the efflux of cells from the BM and into the
inflamed joint, we cannot prove a causal relation for this
mechanism. Monocytes are released from the BM as
Ly6Chigh monocytes and the ratio of Ly6Chigh and Ly6Clow
may be rapidly balanced by systemic factors. Tracking
studies using fluorescent-labeled monocytes are in pro-
gress and will answer to what extent Ly6Chigh monocytes
released from the BM are able to reach the joint in OA.
OA is characterized by cartilage and bone destruction,
which is related to synovitis [6]. A privileged presence of
Ly6Chigh monocytes within the synovium leads to pro-
longed production of inflammatory cytokines (particularly
S100A8/A9) and proteases, which may contribute to joint
destruction. Earlier studies showed that S100A8/A9 is cru-
cial in mediating cartilage and bone destruction within the
CiOA model [22]. S100A8/A9 stimulates chondrocytes to
produce matrix metalloproteinases (MMPs) thereby de-
grading the surrounding ECM [64], which drives synovitis
in a positive feedback loop. In addition, S100A8/A9 dir-
ectly stimulated osteoclastogenesis and strongly increased
osteoclast-mediated bone destruction. The human analogs
of Ly6Chigh and Ly6Clow in the mouse are classical CD14+
+CD16- and non-classical CD14 + CD16+, respectively.
Investigating the balance of these monocyte subsets within
inflammatory OA in synovium and BM may give more
insight into how synovitis and joint destruction are con-
nected to this crippling disease.
In summary we found that S100A8/A9 is a crucial alar-
min involved in favoring recruitment of Ly6Chigh mono-
cytes into the CiOA knee joint. Local production of
S100A8/A9 attracts Ly6Chigh monocytes and may sup-
press their differentiation into Ly6Clow monocytes. More-
over production of S100A8/A9 within the bone marrow
may further promote efflux of Ly6Chigh monocytes into
the circulation. Ly6Chigh monocytes are potent producers
of S100A8/A9 keeping the monocyte population in a pro-
inflammatory state and forming a positive feedback loop.
Understanding the underlying inflammatory process in
the synovium in OA may lead to new therapeutic targets
and inhibiting S100A8/A9 may be an interesting thera-
peutic target to improve the outcome of OA pathology.
Conclusions
Induction of OA leads to the elevation of S100A8/A9 lo-
cally in the joint and systemically in the circulation, and
leads to the mobilization of Ly6Chigh monocytes from
the BM to the joint. S100A8/A9 has an important role
in driving OA pathology, probably by regulating the
local environment in the joint determining whether
Ly6Chigh or Ly6Clow monocytes are recruited.
Additional file
Additional file 1: Figure S1. S100A8/A9 protein levels are systemically
elevated in the serum during early CiOA. Systemic levels of S100A8/A9
protein in serum of WT mice are increased early during CiOA compared
to saline-injected control mice, measured using ELISA. Data represent
mean ± SD of five individual mice per group per time point. *Significantly
different from saline-injected control (*p < 0.05, **p < 0.01, ***p < 0.001).
Figure S2. Expression of adhesion molecules is lower in the BM of WT
mice, compared to S100a9-/- mice, at CiOA day 7. mRNA expression of
several adhesion molecules is lower in the BM of S100a9-/- mice compared to
WT mice at CiOA day 7. Data represent mean ± SD of five individual mice.
*Significantly different from saline-injected control (*p < 0.05, **p < 0.01, ***p
< 0.001). (PPT 142 kb)
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